EPS for Kindred Biosciences, Inc. (KIN) Expected At $-0.38

April 17, 2018 - By Margaret Downey

Kindred Biosciences, Inc. (NASDAQ:KIN) LogoInvestors sentiment decreased to 0.93 in Q4 2017. Its down 1.31, from 2.24 in 2017Q3. It fall, as 12 investors sold Kindred Biosciences, Inc. shares while 16 reduced holdings. 8 funds opened positions while 18 raised stakes. 17.44 million shares or 4.61% less from 18.28 million shares in 2017Q3 were reported.
Bnp Paribas Arbitrage Sa invested in 0% or 7,384 shares. Ariel Invs Limited Com owns 0.21% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 1.96M shares. One Trading L P holds 0% or 29,403 shares. Geode Limited Liability accumulated 206,898 shares. Barclays Public Ltd invested in 3,990 shares or 0% of the stock. Moreover, Parallax Volatility Advisers L P has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN). State Of Wisconsin Investment Board reported 15,000 shares stake. Moreover, Blackrock has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN). Wells Fargo And Mn owns 366,735 shares or 0% of their US portfolio. Susquehanna Limited Liability Partnership owns 10,782 shares. Bankshares Of America De holds 24,160 shares or 0% of its portfolio. Park West Asset Limited Liability stated it has 2.22% in Kindred Biosciences, Inc. (NASDAQ:KIN). Tiaa Cref Inv Management Ltd Liability Corporation reported 61,427 shares. The Pennsylvania-based Vanguard Group Inc has invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Connor Clark Lunn Investment Mgmt Ltd has invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN).

Since January 2, 2018, it had 0 insider buys, and 4 insider sales for $254,552 activity. $167,800 worth of Kindred Biosciences, Inc. (NASDAQ:KIN) was sold by Chin Richard on Monday, April 2.

Analysts expect Kindred Biosciences, Inc. (NASDAQ:KIN) to report $-0.38 EPS on May, 2.They anticipate $0.08 EPS change or 26.67 % from last quarter’s $-0.3 EPS. After having $-0.35 EPS previously, Kindred Biosciences, Inc.’s analysts see 8.57 % EPS growth. The stock increased 0.54% or $0.05 during the last trading session, reaching $9.3. About 50,350 shares traded. Kindred Biosciences, Inc. (NASDAQ:KIN) has risen 18.31% since April 17, 2017 and is uptrending. It has outperformed by 6.76% the S&P500.

Kindred Biosciences, Inc. (NASDAQ:KIN) Ratings Coverage

Among 3 analysts covering Kindred Biosciences (NASDAQ:KIN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Kindred Biosciences had 5 analyst reports since November 17, 2017 according to SRatingsIntel. FBR Capital initiated the stock with “Buy” rating in Monday, February 26 report. The company was maintained on Friday, March 2 by H.C. Wainwright. The firm has “Hold” rating given on Wednesday, December 27 by C.L. King.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $262.16 million. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Kindred Biosciences, Inc. (NASDAQ:KIN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: